Aldeyra Therapeutics (ALDX) Accumulated Expenses (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Accumulated Expenses data on file, last reported at $631516.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 85.19% year-over-year to $631516.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $631516.0 (down 85.19% YoY) and the FY2025 annual result came in at $6.1 million, down 49.5% from the prior year.
• Accumulated Expenses eased to $631516.0 in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $14.4 million in Q1 2023 to a low of $361798.0 in Q3 2025.
• A 5-year average of $6.1 million and a median of $5.8 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 967.83% — and 2025, when it plunged 96.53%.
• Tracing ALDX's Accumulated Expenses over 5 years: stood at $3.8 million in 2022, then retreated by 19.2% to $3.1 million in 2023, then jumped by 292.44% to $12.1 million in 2024, then plunged by 49.5% to $6.1 million in 2025, then tumbled by 89.68% to $631516.0 in 2026.
• The last three Accumulated Expenses figures came in at $631516.0 (Q1 2026), $6.1 million (Q4 2025), and $361798.0 (Q3 2025), per Business Quant data.